Association Between Hospital Size and Outcomes of ES-SCLC Treated with Chemo-ICI: A Real-World Database Study in Japan
- 1Department of Thoracic Oncology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Osaka, Japan
- 2Healthcare Consulting, Inc., Sumitomo Fudosan Chiyoda Fujimi Building, 1-8-19 Fujimi, Chiyoda-ku, Tokyo 102-0071, Japan
- 3Faculty of International Political Science and Economics, Nishogakusha University, 6-16 Sanbancho, Chiyoda-ku, Tokyo 102-8336, Japan
Abstract
Background: Chemotherapy combined with immune checkpoint inhibitors is the standard first-line treatment for extensive-stage small-cell lung cancer. We evaluated whether hospital size, as a surrogate for institutional healthcare resources, was associated with treatment outcomes. Methods: This retrospective observational study used a nationwide electronic medical records database in Japan. Patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line platinum–etoposide plus atezolizumab or durvalumab between 2019 and 2022 were included. Patients were classified by hospital size (<500 vs. ≥500 beds) and compared after propensity score matching. The primary endpoint was time to treatment failure (TTF), and secondary endpoints included grade ≥ 3 hematological toxicities and hepatic impairments. Results: After matching, each group included 81 patients. Median TTF was 4.8 months in the <500-bed group and 4.9 months in the ≥500-bed group. In crude analyses, severe leukopenia occurred in 67.9% of patients in smaller hospitals and 45.7% in larger hospitals (RR, 0.67; 95% CI, 0.51–0.89; p = 0.007), whereas severe neutropenia occurred in 79.0% and 58.0% of patients, respectively (RR, 0.73; 95% CI, 0.59–0.91; p = 0.006). In sensitivity analyses accounting for hospital-level clustering, the association for leukopenia was maintained, whereas that for neutropenia was no longer statistically significant. Conclusions: No clear difference in TTF was observed between the hospital-size groups. Exploratory safety analyses showed differences in severe hematological toxicities, although the findings were not fully consistent after accounting for hospital-level clustering. Further studies are needed to clarify the relationship between institutional healthcare resources and treatment outcomes.
Related
- Visual Acuity Outcomes in Socioeconomically Disadvantaged Patients With Vitreous Hemorrhage Resulting From Proliferative Diabetic Retinopathy Treated at a County Hospital
- Association between maternal dysglycaemia and adverse perinatal outcomes: A retrospective cohort study using a Japanese mother–infant-linked claims database
- Association Between Initial Admission Ward and In-Hospital Mortality Among Patients Hospitalized for Cardiovascular Emergencies ― A Nationwide Study Using the JROAD-DPC Database ―
- Association between glucose-to-lymphocyte ratio and risk of in-hospital mortality in patients with acute ischemic stroke: a retrospective cohort study based on the MIMIC-IV database.
- Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors.
BibTeX
@article{yamanaka2026association,
title = {{Association Between Hospital Size and Outcomes of ES-SCLC Treated with Chemo-ICI: A Real-World Database Study in Japan}},
author = {Yuta Yamanaka and Katsuhiko Iwasaki and Tatsuhiro Uenishi and Fumika Matsushita and Kinya Kokubo and Takayasu Kurata},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213555},
url = {https://www.mdpi.com/2072-6694/18/21/3555},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association Between Hospital Size and Outcomes of ES-SCLC Treated with Chemo-ICI: A Real-World Database Study in Japan
AU - Yuta Yamanaka
AU - Katsuhiko Iwasaki
AU - Tatsuhiro Uenishi
AU - Fumika Matsushita
AU - Kinya Kokubo
AU - Takayasu Kurata
PY - 2026
DA - 2026/11/05
JO - Cancers
DO - 10.3390/cancers18213555
UR - https://www.mdpi.com/2072-6694/18/21/3555
AB - Background: Chemotherapy combined with immune checkpoint inhibitors is the standard first-line treatment for extensive-stage small-cell lung cancer. We evaluated whether hospital size, as a surrogate for institutional healthcare resources, was associated with treatment outcomes. Methods: This retrospective observational study used a nationwide electronic medical records database in Japan. Patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line platinum–etoposide plus atezolizumab or durvalumab between 2019 and 2022 were included. Patients were classified by hospital size (<500 vs. ≥500 beds) and compared after propensity score matching. The primary endpoint was time to treatment failure (TTF), and secondary endpoints included grade ≥ 3 hematological toxicities and hepatic impairments. Results: After matching, each group included 81 patients. Median TTF was 4.8 months in the <500-bed group and 4.9 months in the ≥500-bed group. In crude analyses, severe leukopenia occurred in 67.9% of patients in smaller hospitals and 45.7% in larger hospitals (RR, 0.67; 95% CI, 0.51–0.89; p = 0.007), whereas severe neutropenia occurred in 79.0% and 58.0% of patients, respectively (RR, 0.73; 95% CI, 0.59–0.91; p = 0.006). In sensitivity analyses accounting for hospital-level clustering, the association for leukopenia was maintained, whereas that for neutropenia was no longer statistically significant. Conclusions: No clear difference in TTF was observed between the hospital-size groups. Exploratory safety analyses showed differences in severe hematological toxicities, although the findings were not fully consistent after accounting for hospital-level clustering. Further studies are needed to clarify the relationship between institutional healthcare resources and treatment outcomes.
SN - 2072-6694
ER -